Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 5Carcinoma 2The Diagnosis Was ALK Positive NSCLC 1Solid Tumor 1Neoplasms 1Brain Neoplasms 1ALK-positive Advanced NSCLC 1

Interventions

sotorasib 1pembrolizumab 1osimertinib 1ensartinib 1binimetinib 1Nivolumab 1LY-2157299 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × ensartinib × Thoracic × Clear all
NCT02959619 2023-08-21

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
48 enrolled
Other solid neoplasmThoracic

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡